Clinical Trials Logo

Clinical Trial Summary

The objective of this clinical feasibility study is to evaluate initial clinical safety and device performance of the CellFX Percutaneous Electrode (PE) System for the treatment of symptomatic benign thyroid nodules.


Clinical Trial Description

Cohort 1: (CellFX PE Procedure and Surgery) The first five enrolled subjects will be patients with planned thyroidectomy. The site investigator will perform the CellFX procedure followed by an ultrasound evaluation. The site investigator will then perform a partial or total thyroidectomy. Tissue samples from the CellFX targeted treated areas will be sent to the pathology lab for gross and histological evaluation. The participant will exit the study on the same day of surgery. Cohort 2: (CellFX PE Procedure with 12 months follow-up) When Cohort 1 is completed, up to 25 subjects will undergo a CellFX treatment using a percutaneous approach under ultrasound guidance. After CellFX treatment, all subjects will be followed weekly until 1 month, 3 months, 6 months and 12 months post-CellFX PE procedure. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06117085
Study type Interventional
Source Pulse Biosciences, Inc.
Contact William Knape
Phone (510) 906-4649
Email bknape@pulsebiosciences.com
Status Recruiting
Phase N/A
Start date April 13, 2023
Completion date February 28, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04410601 - Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT N/A
Not yet recruiting NCT05758038 - US-guided RFA vs MWA in the Treatment of Benign Thyroid Nodules
Not yet recruiting NCT04298684 - Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes Phase 4
Recruiting NCT04666103 - Function Integrity of Neck Anatomy in Thyroid Surgery N/A
Not yet recruiting NCT04233398 - HIFU Treatment of Benign Thyroid Nodules N/A